MedTrace Logo

13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer

NCT00002586 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2020-05-15

No results posted yet for this study

Summary

RATIONALE: 13 Cis retinoic acid may prevent the development of cancer cells.

PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of 13-cis retinoic acid with or without vitamin E for chemoprevention or observation of cancer in persons at high risk of developing lung cancer.

Conditions

Interventions

DRUG

13-cis retinoic acid

DIETARY_SUPPLEMENT

Tocopherol

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • York E. Miller, MD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-01-31
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002586 on ClinicalTrials.gov